Spot shows folks running as a symbol of how the health-challenged can chase their dreams because of Sanofi meds.

Discover Regeneron’s Q3 2025 earnings: strong Dupixent, Libtayo & EYLEA HD growth, R&D updates, plus key manufacturing and regulatory challenges.

In this Healio video exclusive, Leonard H. Calabrese, DO, chief medical editor of Healio Rheumatology, highlights a pair of “timely and cool” stories on point-of-care AI use and the FDA approval of ...

With a new approach to creating thymus-targeted medicines for autoimmune diseases, Zag Bio has emerged from stealth with the ...

Sanofi India Limited ( ($IN:SANOFI) ) has shared an announcement. Sanofi India Limited has announced the appointment of Mr. Deepak Arora as the ...

The MoU supports Saudi Vision 2030 and the National Transformation Program’s focus on localizing healthcare manufacturing ...

Q3 2025 Earnings Call October 24, 2025 8:30 AM EDTCompany ParticipantsThomas Larsen - Head of Investor RelationsPaul Hudson - CEO ...

Pharmaceutical launches and increased demand for its blockbuster Dupixent drug lifted net sales by 7% in the third quarter.

Sanofi said new medicine generated sales of 1 billion euros, up 57% from the same period last year. It said sales of the anti-inflammatory treatment Dupixent--developed jointly with Regeneron--jumped ...